Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:FKBP9-RNPEP

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: FKBP9-RNPEP
	FusionPDB ID: 30544
	FusionGDB2.0 ID: 30544
		Hgene	Tgene
	Gene symbol	FKBP9	RNPEP
	Gene ID	11328	6051
	Gene name	FKBP prolyl isomerase 9	arginyl aminopeptidase
	Synonyms	FKBP60\|FKBP63\|PPIase	AP-B\|APB
	Cytomap	7p14.3	1q32.1
	Type of gene	protein-coding	protein-coding
	Description	peptidyl-prolyl cis-trans isomerase FKBP963 kDa FK506-binding protein63 kDa FKBPFK506 binding protein 9, 63 kDaFK506-binding protein 9FKBP-63FKBP-9PPIase FKBP9rotamase	aminopeptidase Barginine aminopeptidase
	Modification date	20200313	20200320
	UniProtAcc	Q75LS8 Main function of 5'-partner protein:	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000242209, ENST00000490776, ENST00000538336, ENST00000538443, ENST00000489038,	ENST00000471105, ENST00000367286, ENST00000295640,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	7 X 7 X 4=196	7 X 7 X 5=245
	# samples	7	9
	** MAII score	log2(7/196*10)=-1.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(9/245*10)=-1.4447848426729 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: FKBP9 [Title/Abstract] AND RNPEP [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: FKBP9 [Title/Abstract] AND RNPEP [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	FKBP9(33035961)-RNPEP(201965274), # samples:1
Anticipated loss of major functional domain due to fusion event.	FKBP9-RNPEP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FKBP9-RNPEP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FKBP9-RNPEP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. FKBP9-RNPEP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:33035961/chr1:201965274)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across FKBP9 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across RNPEP (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000242209

FKBP9

chr7

33035961

ENST00000295640

RNPEP

chr1

201965274

3042

1395

169

2610

813

ENST00000538336

FKBP9

chr7

33035961

ENST00000295640

RNPEP

chr1

201965274

3165

1518

133

2733

866

ENST00000538443

FKBP9

chr7

33035961

ENST00000295640

RNPEP

chr1

201965274

2827

1180

365

2395

676

ENST00000490776

FKBP9

chr7

33035961

ENST00000295640

RNPEP

chr1

201965274

2255

608

1823

581

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000242209	ENST00000295640	FKBP9	chr7	33035961	+	RNPEP	chr1	201965274	+	0.001116205	0.9988838
ENST00000538336	ENST00000295640	FKBP9	chr7	33035961	+	RNPEP	chr1	201965274	+	0.000642255	0.99935776
ENST00000538443	ENST00000295640	FKBP9	chr7	33035961	+	RNPEP	chr1	201965274	+	0.001801329	0.9981987
ENST00000490776	ENST00000295640	FKBP9	chr7	33035961	+	RNPEP	chr1	201965274	+	0.001279029	0.99872094

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FKBP9-RNPEP

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
FKBP9	chr7	33035961	RNPEP	chr1	201965274	1180	272	NASLLDGTLLDSTSRVWAEPCLIDAA
FKBP9	chr7	33035961	RNPEP	chr1	201965274	1395	409	NASLLDGTLLDSTSRVWAEPCLIDAA
FKBP9	chr7	33035961	RNPEP	chr1	201965274	1518	462	NASLLDGTLLDSTSRVWAEPCLIDAA
FKBP9	chr7	33035961	RNPEP	chr1	201965274	608	177	NASLLDGTLLDSTSRVWAEPCLIDAA

Top

Potential FusionNeoAntigen Information of FKBP9-RNPEP in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

FKBP9-RNPEP_33035961_201965274.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:01	LLDSTSRVW	0.9988	0.9919	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:22	TLLDSTSRV	0.9975	0.7058	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:02	LLDSTSRVW	0.996	0.948	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:01	LLDSTSRVW	0.9952	0.9837	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:27	TLLDSTSRV	0.9946	0.7039	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:13	TLLDSTSRV	0.9936	0.7433	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:38	TLLDSTSRV	0.9935	0.7478	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:16	TLLDSTSRV	0.9924	0.6168	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:24	TLLDSTSRV	0.9922	0.7042	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:60	TLLDSTSRV	0.9922	0.674	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:67	TLLDSTSRV	0.9922	0.7042	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:30	TLLDSTSRV	0.9922	0.7042	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:11	TLLDSTSRV	0.9915	0.7463	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:21	TLLDSTSRV	0.99	0.8227	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:35	TLLDSTSRV	0.9894	0.714	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:03	LLDSTSRVW	0.9874	0.9952	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:19	TLLDSTSRV	0.9809	0.5148	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:04	TLLDSTSRV	0.9791	0.6923	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A32:13	LLDSTSRVW	0.9771	0.9854	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:29	TLLDSTSRV	0.9747	0.7061	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:20	TLLDSTSRV	0.9695	0.7069	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:17	TLLDSTSRV	0.9668	0.5576	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B13:02	TLLDSTSRV	0.0373	0.6762	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:01	TLLDSTSRVW	0.9997	0.9803	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:01	TLLDSTSRVW	0.9945	0.962	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:22	GTLLDSTSRV	0.9802	0.5379	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:38	GTLLDSTSRV	0.972	0.6706	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A32:13	TLLDSTSRVW	0.9706	0.9777	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:13	GTLLDSTSRV	0.964	0.6555	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:27	GTLLDSTSRV	0.9558	0.6126	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:24	GTLLDSTSRV	0.9447	0.5728	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:30	GTLLDSTSRV	0.9447	0.5728	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:67	GTLLDSTSRV	0.9447	0.5728	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:16	GTLLDSTSRV	0.9424	0.5047	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:35	GTLLDSTSRV	0.9415	0.5761	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:29	GTLLDSTSRV	0.86	0.5716	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:01	GTLLDSTSRVW	1	0.9797	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:02	GTLLDSTSRVW	0.9999	0.9031	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:01	GTLLDSTSRVW	0.9998	0.9604	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:03	GTLLDSTSRVW	0.9997	0.9908	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C05:09	LLDSTSRV	1	0.9642	8	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C08:15	LLDSTSRV	0.9993	0.9835	8	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:05	TLLDSTSRV	0.9965	0.5758	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C05:09	LLDSTSRVW	0.9961	0.973	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:07	TLLDSTSRV	0.9926	0.7179	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:01	TLLDSTSRV	0.9922	0.7042	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B44:08	LLDSTSRVW	0.6868	0.7543	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:01	GTLLDSTSRV	0.9447	0.5728	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C05:01	LLDSTSRV	1	0.9642	8	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C04:03	LLDSTSRV	1	0.8941	8	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C08:02	LLDSTSRV	0.9993	0.9835	8	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:10	LLDSTSRVW	0.9988	0.9919	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:03	TLLDSTSRV	0.9966	0.7243	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:04	LLDSTSRVW	0.9965	0.783	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-C05:01	LLDSTSRVW	0.9961	0.973	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:06	LLDSTSRVW	0.9916	0.908	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:06	TLLDSTSRV	0.99	0.8227	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:14	TLLDSTSRV	0.99	0.7705	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A32:01	LLDSTSRVW	0.9802	0.9823	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:02	LLDSTSRVW	0.9757	0.9381	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B15:13	LLDSTSRVW	0.9214	0.8801	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A69:01	TLLDSTSRV	0.8389	0.7771	7	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B15:24	LLDSTSRVW	0.8185	0.9579	8	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:10	TLLDSTSRVW	0.9997	0.9803	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:04	TLLDSTSRVW	0.9992	0.7531	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B15:24	TLLDSTSRVW	0.9983	0.8984	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:02	TLLDSTSRVW	0.991	0.9414	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-A02:03	GTLLDSTSRV	0.9832	0.6083	6	16
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B15:13	TLLDSTSRVW	0.9601	0.7851	7	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:10	GTLLDSTSRVW	1	0.9797	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B58:06	GTLLDSTSRVW	0.9999	0.9112	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:04	GTLLDSTSRVW	0.9999	0.8088	6	17
FKBP9-RNPEP	chr7	33035961	chr1	201965274	1395	HLA-B57:02	GTLLDSTSRVW	0.9998	0.9751	6	17

Top

Potential FusionNeoAntigen Information of FKBP9-RNPEP in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of FKBP9-RNPEP

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3175	GTLLDSTSRVWAEP	FKBP9	RNPEP	chr7	33035961	chr1	201965274	1395

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FKBP9-RNPEP

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3175	GTLLDSTSRVWAEP	-7.15543	-7.26883
HLA-B14:02	3BVN	3175	GTLLDSTSRVWAEP	-4.77435	-5.80965
HLA-B52:01	3W39	3175	GTLLDSTSRVWAEP	-6.80875	-6.92215
HLA-B52:01	3W39	3175	GTLLDSTSRVWAEP	-4.20386	-5.23916
HLA-A11:01	4UQ2	3175	GTLLDSTSRVWAEP	-7.5194	-8.5547
HLA-A11:01	4UQ2	3175	GTLLDSTSRVWAEP	-6.9601	-7.0735
HLA-A24:02	5HGA	3175	GTLLDSTSRVWAEP	-7.52403	-7.63743
HLA-A24:02	5HGA	3175	GTLLDSTSRVWAEP	-5.82433	-6.85963
HLA-B27:05	6PYJ	3175	GTLLDSTSRVWAEP	-3.28285	-4.31815
HLA-B44:05	3DX8	3175	GTLLDSTSRVWAEP	-5.91172	-6.94702
HLA-B44:05	3DX8	3175	GTLLDSTSRVWAEP	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of FKBP9-RNPEP

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
FKBP9-RNPEP	chr7	33035961	chr1	201965274	6	16	GTLLDSTSRV	TGGGACCCTGCTGGACTCCACGAGCCGGGT
FKBP9-RNPEP	chr7	33035961	chr1	201965274	6	17	GTLLDSTSRVW	TGGGACCCTGCTGGACTCCACGAGCCGGGTGTG
FKBP9-RNPEP	chr7	33035961	chr1	201965274	7	16	TLLDSTSRV	GACCCTGCTGGACTCCACGAGCCGGGT
FKBP9-RNPEP	chr7	33035961	chr1	201965274	7	17	TLLDSTSRVW	GACCCTGCTGGACTCCACGAGCCGGGTGTG
FKBP9-RNPEP	chr7	33035961	chr1	201965274	8	16	LLDSTSRV	CCTGCTGGACTCCACGAGCCGGGT
FKBP9-RNPEP	chr7	33035961	chr1	201965274	8	17	LLDSTSRVW	CCTGCTGGACTCCACGAGCCGGGTGTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of FKBP9-RNPEP

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SARC	FKBP9-RNPEP	chr7	33035961	ENST00000242209	chr1	201965274	ENST00000295640	TCGA-DX-A48O

Top

Potential target of CAR-T therapy development for FKBP9-RNPEP

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to FKBP9-RNPEP

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to FKBP9-RNPEP

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)